Lilly, Lupin enter diabetes partnership

NEW DELHI — Eli Lilly’s India division and Indian generic drug maker Lupin will distribute Lilly’s insulin products in India and Nepal under an agreement between the two companies announced Friday.

Under the collaboration, Lilly and Lupin will promote and distribute Huminsulin R, Huminsulin NPH, Huminsulin 50/50, Huminsulin 30/70 and Humapen Ergo II. The companies said the deal would double the current customer base.

India currently has about 51 million people living with diabetes and is expected to have 85 million by 2030, accounting for nearly one-fifth of all patients with the disease.